Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023

BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that new data from studies with NUZYRA^® (omadacycline) will be presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).

Read more at globenewswire.com